English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

In vivo mutation rates and the landscape of fitness costs of HIV-1

MPS-Authors

Zanini,  Fabio
Max Planck Institute for Developmental Biology, Max Planck Society;
Department of Bioengineering, Stanford University;

Puller,  Vadim
Max Planck Institute for Developmental Biology, Max Planck Society;

Neher,  Richard A.
Max Planck Institute for Developmental Biology, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Zanini, F., Puller, V., Brodin, J., Albert, J., & Neher, R. A. (2017). In vivo mutation rates and the landscape of fitness costs of HIV-1. VIRUS EVOLUTION, 3(1): UNSP vex003. doi:10.1093/ve/vex003.


Cite as: https://hdl.handle.net/21.11116/0000-0002-1A9A-4
Abstract
Mutation rates and fitness costs of deleterious mutations are difficult to measure in vivo but essential for a quantitative understanding of evolution. Using whole genome deep sequencing data from longitudinal samples during untreated HIV-1 infection, we estimated mutation rates and fitness costs in HIV-1 from the dynamics of genetic variation. At approximately neutral sites, mutations accumulate with a rate of 1.2x10(-5) per site per day, in agreement with the rate measured in cell cultures. We estimated the rate from G to A to be the largest, followed by the other transitions C to T, T to C, and A to G, while transversions are less frequent. At other sites, mutations tend to reduce virus replication. We estimated the fitness cost of mutations at every site in the HIV-1 genome using a model of mutation selection balance. About half of all non-synonymous mutations have large fitness costs (>10 percent), while most synonymous mutations have costs <1 percent. The cost of synonymous mutations is especially low in most of pol where we could not detect measurable costs for the majority of synonymous mutations. In contrast, we find high costs for synonymous mutations in important RNA structures and regulatory regions. The intra-patient fitness cost estimates are consistent across multiple patients, indicating that the deleterious part of the fitness landscape is universal and explains a large fraction of global HIV-1 group M diversity.